RSVSanofi’s/Astazeneca’s anti-RSV antibody highly effectiveLatest NewsNHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial. Read more 12 May 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/Respiratory_Syncytial_Virus__RSV_.jpeg 310 450 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-05-12 14:26:002024-07-12 11:29:49Sanofi’s/Astazeneca’s anti-RSV antibody highly effective